Pelthos Therapeutics Inc.
PTHS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,179 | $2,579 | $392 | $209 |
| G&A Expenses | $6,392 | $4,283 | $1,926 | $630 |
| SG&A Expenses | $6,392 | $4,283 | $1,926 | $630 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7,571 | $6,862 | $2,318 | $839 |
| Operating Income | -$7,571 | -$6,862 | -$2,318 | -$839 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$384 | -$519 | -$140 | $244 |
| Pre-Tax Income | -$7,955 | -$7,381 | -$2,459 | -$595 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,955 | -$7,381 | -$2,459 | -$595 |
| % Margin | – | – | – | – |
| EPS | -13.54 | -12.8 | -4.26 | -1 |
| % Growth | -5.8% | -200.5% | -326% | – |
| EPS Diluted | -13.54 | -12.8 | -4.26 | -1 |
| Weighted Avg Shares Out | 588 | 577 | 577 | 577 |
| Weighted Avg Shares Out Dil | 588 | 577 | 577 | 577 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $786 | $519 | $140 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7,169 | -$6,862 | -$2,318 | -$595 |
| % Margin | – | – | – | – |